{"id":675664,"date":"2023-11-07T20:10:01","date_gmt":"2023-11-07T20:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675664"},"modified":"2023-11-07T20:10:01","modified_gmt":"2023-11-07T20:10:01","slug":"allergic-rhinitis-pipeline-clinical-trials-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/allergic-rhinitis-pipeline-clinical-trials-key-companies_675664.html","title":{"rendered":"Allergic Rhinitis Pipeline, Clinical Trials, Key Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Allergic Rhinitis Pipeline, Clinical Trials, Key Companies \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Allergic Rhinitis Pipeline, Clinical Trials, Key Companies \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cAllergic Rhinitis &#8211; Pipeline Insight, 2023,\u201d report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;Allergic Rhinitis &#8211; Pipeline Insight, 2023,&rdquo; report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">Some of the key Highlights for Allergic Rhinitis&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The Key Companies working for Allergic Rhinitis include Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals Inc., Revolo Biotherapeutics and many others&nbsp;<\/li>\n<li>The Key Therapies working for Allergic Rhinitis include REGN5713-5714-5715, MM09-MG01, and many others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Got queries? Click here to know more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Allergic Rhinitis&nbsp;<\/a><\/p>\n<p style=\"text-align: justify;\">Allergic Rhinitis Overview<\/p>\n<p style=\"text-align: justify;\">Allergic rhinitis (AR) is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. It affects one in six individuals and is associated with significant morbidity, loss of productivity, and healthcare costs. Historically, AR was thought to be a disease process of the nasal airway alone. Still, the development of the unified airway theory has classified AR as a component of systemic allergic response, with other associated conditions, such as asthma and atopic dermatitis, sharing an underlying systemic pathology. AR can be classified as either seasonal (intermittent) or perennial (chronic), with approximately 20% of cases being seasonal, 40% perennial, and 40% with features of both<\/p>\n<p style=\"text-align: justify;\">There are approx. 35+ key companies which are developing the therapies for Allergic Rhinitis. The companies which have their Allergic Rhinitis drug candidates in the mid to advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals.<\/p>\n<h2 style=\"text-align: justify;\">Phases<\/h2>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Report covers around 35+ products under different phases of clinical development like<\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued and inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravitreal<\/li>\n<li>Subretinal<\/li>\n<li>Topical<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drugs have been categorized under various product types like Mono, Combination and Mono\/Combination.<\/p>\n<p style=\"text-align: justify;\">Learn more by requesting for sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Allergic Rhinitis&nbsp;<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Allergic Rhinitis Key Companies<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Hanmi Pharmaceutical<\/li>\n<li>Immunotek<\/li>\n<li>Anhui Palo&nbsp;<\/li>\n<li>Alto Pharmaceuticals Inc<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Allergic Rhinitis Therapies<\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;REGN5713-5714-5715<\/li>\n<li>MM09-MG01<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Table of Contents<\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;Key Insights&nbsp;<\/li>\n<li>&nbsp;Report Introduction&nbsp;<\/li>\n<li>&nbsp;Executive Summary of Allergic Rhinitis&nbsp;<\/li>\n<li>&nbsp;Disease Background and Overview<\/li>\n<li>&nbsp;Epidemiology and patient population<\/li>\n<li>&nbsp;The United States&nbsp;<\/li>\n<li>&nbsp;EU 5<\/li>\n<li>&nbsp;Allergic Rhinitis Emerging Therapies<\/li>\n<li>&nbsp;Allergic Rhinitis Market Outlook<\/li>\n<li>&nbsp;Market Access and Reimbursement of Therapies<\/li>\n<li>&nbsp;Appendix<\/li>\n<li>Allergic Rhinitis&nbsp; Report Methodology<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<\/ul>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=allergic-rhinitis-pipeline-clinical-trials-key-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=allergic-rhinitis-pipeline-clinical-trials-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cAllergic Rhinitis &#8211; Pipeline Insight, 2023,\u201d report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/allergic-rhinitis-pipeline-clinical-trials-key-companies_675664.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-675664","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675664"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675664\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}